# Enflonsia (clesrovimab-cfor) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/clesrovimab-cfor

> The FDA approved Enflonsia (clesrovimab-cfor), sponsored by Merck & Co., Inc. (MRK), on June 9, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Enflonsia (clesrovimab-cfor) FDA approved?

Yes. The FDA approved Enflonsia (clesrovimab-cfor), sponsored by Merck & Co., Inc. (MRK), on June 9, 2025. FDA novel drug approvals: "Enflonsia | clesrovimab-cfor | 6/9/2025 | To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season Drug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/clesrovimab-cfor)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/clesrovimab-cfor#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Enflonsia (clesrovimab-cfor) |
| Codes |  |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### June 9, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Enflonsia | clesrovimab-cfor | 6/9/2025 | To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season Drug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- openFDA Drugs@FDA: "BLA761432 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250609, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product ENFLONSIA (CLESROVIMAB-CFOR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761432%22

### October 14, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761432 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20261014, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product ENFLONSIA (CLESROVIMAB-CFOR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761432%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/clesrovimab-cfor.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Enflonsia (clesrovimab-cfor) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/clesrovimab-cfor

```bibtex
@misc{secapidev_pdufa_clesrovimab_cfor_20261116,
  title        = {Enflonsia (clesrovimab-cfor) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/clesrovimab-cfor}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_clesrovimab_cfor_20261116","title":"Enflonsia (clesrovimab-cfor) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/clesrovimab-cfor","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
